| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.5 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.029 | 0.5 |
| mRNA | importazole | CTRPv2 | pan-cancer | AAC | -0.026 | 0.5 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.023 | 0.5 |
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.024 | 0.5 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | -0.02 | 0.5 |
| mRNA | Midostaurin | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | SZ4TA2 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.5 |